Gök Yurttaş, AsiyeOkat, ZehraElgün, TuğbaUçar Çifçi, KezbanSevim, Altuğ Mert2023-02-242023-02-242023Gök Yurttaş, A., Okat, Z., Elgün, T., Uçar Çifçi, K. & Sevim, A. M. (2023). Genetic deviation associated with photodynamic therapy in hela cell. Photodiagnosis and Photodynamic Therapy, 42, pp. 1-9. https://doi.org/10.1016/j.pdpdt.2023.1033461572-10001873-1597https://doi.org/10.1016/j.pdpdt.2023.103346https://hdl.handle.net/20.500.13055/399Photodynamic therapy (PDT) is a crucial method that is used in cancer treatment. Entering the program for PDT selection today gives a new direction. The main therapeutic effect is the production of singlet oxygen (1O2), which activates the photosensitizer (PS). Phthalocyanines for PDT applications are preferred because they produce high singlet oxygen with absorbers of about 600-700 nm. Aim It is aimed to analyze cancer cell pathways by flow cytometry analysis and cancer-related genes with q-PCR device by applying phthalocyanine L1ZnPC, which we use as photosensitizer in photodynamic therapy, in HELA cell line. In this study, we investigate the molecular basis of L1ZnPC's anti-cancer activity. Material method The cytotoxic effects of L1ZnPC, a phthalocyanine obtained from our previous study, in HELA cells were evaluated and it was determined that it led to a high rate of death as a result. The result of photodynamic therapy was analyzed using q-PCR. From the data received at the conclusion of this investigation, gene expression values were calculated, and expression levels were assessed using the 2−∆∆Ct method to examine the relative changes in these values. Cell death pathways were interpreted with the FLOW cytometer device. One-Way Analysis of Variance (ANOVA) and the Tukey-Kramer Multiple Comparison Test with Post-hoc Test were used for the statistical analysis. Conclusion In our study, it was observed that HELA cancer cells underwent apoptosis at a rate of 80% with drug application plus photodynamic therapy by flow cytometry method. According to q-PCR results, CT values ​​of eight out of eighty-four genes were found to be significant and their association with cancer was evaluated. L1ZnPC is a new phthalocyanine used in this study and our findings should be supported by further studies. For this reason, different analyses are needed to be performed with this drug in different cancer cell lines. In conclusion, according to our results, this drug looks promising but still needs to be analyzed through new studies. It is necessary to examine in detail which signaling pathways they use and their mechanism of action. For this, additional experiments and animal studies are required.eninfo:eu-repo/semantics/closedAccessL1znpcPhotodynamic TherapyPhthalocyaninesHELA CellCancerApoptosisCDC20DDIT3Article10.1016/j.pdpdt.2023.1033464219Q3WOS:0009497987000012-s2.0-85149425232PMID: 36809810Q1